OGT to Sell Cytocell Products Direct in North America
Complete the form below to unlock access to ALL audio articles.
Oxford Gene Technology has announced that following its acquisition of Cytocell in March, it will directly sell Cytocell products to the North American market from the 1st June 2014. New and existing Cytocell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months.
OGT’s acquisition of Cytocell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure™ cytogenetics array and Genefficiency™ next generation sequencing products and services, expanding the company’s genomic medicine offering.
Dr Martin Lawrie, Managing Director of Cytocell said: “The global cytogenetics market is predicted to grow by 23% a year to $2 billion by 2019, and with North America accounting for approximately 50% of the market, OGT is now well placed to better serve this increasing customer base with a wider range of products. The integration of Cytocell into the OGT group has proceeded extremely smoothly with very positive, immediate benefits for our customers. OGT’s excellent and expanding sales team will provide our customers with the best possible sales and support experience moving forward.”
